Vesilasin

Vesilasin is a medication used to treat certain types of cancer, specifically non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It is a small molecule inhibitor that targets the vascular endothelial growth factor receptor 2 (VEGFR2), a protein involved in the growth and survival of cancer cells. By inhibiting VEGFR2, vesilasin can slow the growth of cancer cells and potentially improve survival rates in patients with lung cancer.

Vesilasin was approved by the U.S. Food and Drug Administration (FDA) in 2015 for the treatment of NSCLC and SCLC. It is typically administered intravenously and is often used in combination with other chemotherapy drugs to enhance its effectiveness. The drug is available in various formulations, including tablets and injectable solutions.

Common side effects of vesilasin may include fatigue, nausea, vomiting, diarrhea, and hypertension. Serious side effects can occur, such as bleeding, infection, and low blood cell counts, which may require medical intervention. Patients should be closely monitored during treatment to manage these potential side effects and ensure their safety.

Vesilasin is not a first-line treatment for lung cancer but is often used in later stages of the disease when other treatments have failed. Its use is typically determined by a healthcare provider based on the patient's specific condition and medical history. As with any medication, patients should discuss the benefits and risks of vesilasin with their healthcare provider to make an informed decision about its use.